首页>
外国专利>
PEPTIDES FOR USE IN THE TOPICAL TREATMENT OF RETINAL NEURODEGENERATIVE DISESASES, IN PARTICULAR IN EARLY STAGES OF DIABETIC RETINOPATHY AND OTHER RETINAL DISEASES IN WHICH NEURODEGENERATION PLAYS AN ESSENTIAL ROLE
PEPTIDES FOR USE IN THE TOPICAL TREATMENT OF RETINAL NEURODEGENERATIVE DISESASES, IN PARTICULAR IN EARLY STAGES OF DIABETIC RETINOPATHY AND OTHER RETINAL DISEASES IN WHICH NEURODEGENERATION PLAYS AN ESSENTIAL ROLE
Peptides with a sequence length from 13 to 50 amino acids, the N-terminal region of said peptides consisting in the sequence HXaa1EGTFTSDXaa2SXaa3Xaa4 (SEQ ID NO: 1) wherein: Xaa1 is an amino acid selected from alanine and glycine; Xaa2 is an amino acid selected from valine and leucine; Xaa3 is an amino acid selected from serine and lysine; Xaa4 is an amino acid selected from tyrosine and glutamine; and Hystidine is the N-terminal residue; for use in the topical treatment and/or prevention of retinal neurodegenerative diseases, in particular diabetic retinopathy are described. Pharmaceutical topical compositions for use in the topical treatment and/or prevention of these diseases are also described.
展开▼
机译:具有13至50个氨基酸的序列长度的肽,所述肽的N端区域由序列HXaa1EGTFTSDXaa2SXaa3Xaa4(SEQ ID NO:1)组成,其中:Xaa1是选自丙氨酸和甘氨酸的氨基酸;和Xaa2是选自缬氨酸和亮氨酸的氨基酸; Xaa3是选自丝氨酸和赖氨酸的氨基酸; Xaa4是选自酪氨酸和谷氨酰胺的氨基酸;吡啶是N末端残基。用于局部治疗和/或预防视网膜神经退行性疾病,特别是糖尿病性视网膜病的药物描述。还描述了用于局部治疗和/或预防这些疾病的药物局部组合物。
展开▼